We showed that a Candida albicans petite mutant in which oxidative phosphorylation is uncoupled was eightfold more resistant to fluconazole and voriconazole than SC5314 but equally susceptible to ketoconazole, itraconazole, and amphotericin B. Strain P5 significantly overexpressed MDR1, which likely accounts for the decreased drug susceptibility.
The azole antifungal agents are widely used to treat diverse Candida albicans infections. Resistance to these drugs can contribute to treatment failures (28, 29) . The molecular bases of resistance are best characterized for fluconazole (12, 23, 42) . Mechanisms include drug efflux due to overexpression of ATPbinding cassette (ABC) transporters encoded by CDR1 and CDR2 (10, 30, 32) and major facilitator transporters encoded by MDR1 and FLU1 (5, 15, 30); increased expression of ERG11, which encodes the target enzyme 14-␣-demethylase; mutations in ERG11 (21, 38); and mutations in ERG3 that inactivate ⌬ 5,6 desaturase and cause accumulation of growthsupporting 14␣-methylfecosterol (19, 20, 27) . More recently, aneuploidy, particularly of chromosome 5, has been implicated and considered likely due to increased copy numbers of ERG11 and other genes (36) .
Petite mutant strains of Candida glabrata and Saccharomyces cerevisiae are resistant to fluconazole and other azoles through mechanisms that are not fully defined (1-4, 34, 42) . Although a C. albicans petite mutant was tolerant to amphotericin B (14), susceptibility of such strains to azoles is unknown. In a previous study, we serially passed C. albicans strain SC5314 through the spleens of mice and recovered a petite mutant (called P5) in which oxidative phosphorylation was uncoupled (7). The primary objectives of this study were to determine the susceptibility of SC5314 and strain P5 to azoles and, in the event of differences, to study previously characterized mechanisms of resistance.
Using a standard broth macrodilution method (24), we found the MICs of fluconazole and voriconazole to be eightfold higher against strain P5 than SC5314 but still within susceptible ranges (Table 1 ). The MICs of ketoconazole and itraconazole did not differ between the strains, nor did MICs of amphotericin B (Table 1) . Moreover, amphotericin B time-kill curves (8) were similar at drug concentrations 0.25ϫ and 1ϫ MIC (Fig. 1) .
We used a broth microdilution method to measure the MICs of several drugs that are structurally unrelated to fluconazole but subjected to efflux by ABC and/or Mdr1p transporters Table 2) , we demonstrated that MDR1 expression was upregulated in strain P5 and CDR1 was up-regulated in SC5314 (data not shown). Levels of CDR2 expression were very low in both strains. The expression of ERG11, ERG3, and FLU1 did not differ between the strains. To corroborate and better quantify our findings for MDR1, CDR1, and CDR2, we performed real-time RT-PCR ( Table 2) . We demonstrated that expression of MDR1 by strain P5 was 8.3-to 12.5-fold greater than by SC5314, whereas expression of CDR1 was 3.1-to 5.7-fold lower ( Table 3 ). The expression of CDR2 by strain P5 was slightly higher than by SC5314 (Table 3) .
The sequence of ERG11 in strain P5 differed at two residues from that of our SC5314 strain and the published sequence (http://www.candidagenome.org/): F14S and A409T. ERG3 sequences did not differ from the published sequence. Using whole-genome single-nucleotide polymorphism (SNP) microarrays to analyze the strains' genotypes (11), we found that the SNP profiles were identical. These results effectively excluded aneuploidy (A. Forche, personal communication).
To our knowledge, this is the first study of azole susceptibility in a C. albicans petite mutant strain. Similar to strain P5, previously described C. glabrata petite mutants have shown diminished susceptibility to fluconazole. Our results differed in several ways from earlier reports, however. Most notably, the C. glabrata petite mutants were fully resistant to both fluconazole and itraconazole, which was attributed to up-regulation of CDR1 with a lesser contribution from CDR2 (2, 3, 34) . In strain P5, the diminished susceptibilities to fluconazole and 26, 30, 31, 37, 41) , cycloheximide, which is pumped by both Mdr1p and ABC transporters, and rhodamine 6G, which is pumped by ABC transporters only. Finally, we excluded other molecular causes of resistance, including overexpression of ERG11, mutations in ERG3, or aneuploidy. The ERG11 mutations in strain P5 have not been previously associated with diminished azole susceptibility (33) . Nevertheless, we cannot definitively conclude that they did not contribute to our results, particularly since the levels of drug resistance were low. Indeed, we must acknowledge that C. albicans is likely to possess as-yetuncharacterized resistance mechanisms (39) which might also have influenced our findings.
Whereas petite mutant yeasts have generally demonstrated diminished azole susceptibility, amphotericin B results have been less consistent. In addition to our findings, amphotericin B-tolerant C. albicans and hypersusceptible C. glabrata strains have been previously reported (2, 3, 9, 13, 14). The diverse types of mitochondrial damage that cause petite mutant phenotypes are known to alter sterol synthesis in different ways (13, 14). Results to date suggest that the alterations to synthetic pathways have more consistent effects on susceptibility to azoles than amphotericin B. Along these lines, strain P5 is potentially a unique tool with which to study relationships between mitochondrial function, oxidative phosphorylation, sterol synthesis, and mechanisms of azole resistance.
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